Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Study of Pemetrexed for Second-Line Pancreas Cancer

This study has been terminated.
(At interim analysis the study did not meet the response criteria to continue)
Eli Lilly and Company
Information provided by:
Georgetown University Identifier:
First received: March 17, 2009
Last updated: March 23, 2011
Last verified: March 2011

March 17, 2009
March 23, 2011
October 2007
July 2009   (final data collection date for primary outcome measure)
Progression-free survival [ Time Frame: 6 months after last patient enrolled ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT00864513 on Archive Site
  • Objective response [ Time Frame: end of study treatment ] [ Designated as safety issue: No ]
  • Time to progression [ Time Frame: 6 months after last patient enrolled ] [ Designated as safety issue: No ]
  • CA 19-9 response [ Time Frame: end of study treatment ] [ Designated as safety issue: No ]
  • Toxicities [ Time Frame: 30 days after last dose of study drug ] [ Designated as safety issue: Yes ]
Same as current
Not Provided
Not Provided
Study of Pemetrexed for Second-Line Pancreas Cancer
A Phase II Study of Pemetrexed as Second-Line Treatment in Patients With Pancreatic Cancer Progressing Despite Therapy With Gemcitabine

This study is for patients with pancreatic cancer that has grown and/or spread after having previously received the standard chemotherapy drug called gemcitabine.

In this study a drug called pemetrexed is being tested. This drug is approved by the FDA for use in lung cancer and mesothelioma. The purpose of this study is to see if pemetrexed keeps pancreas cancer that has grown and/or spread after gemcitabine from growing. Subjects will receive pemetrexed IV once every 21 days until disease progression or unacceptable side effects occur.

This is an open label Phase II trial using pemetrexed as second-line treatment in patients with advanced pancreatic cancer progressing within six months of prior gemcitabine-based therapy. Subjects will receive pemetrexed 500 mg/m2 IV every 21 days until disease progression or unacceptable toxicity.

Phase 2
Allocation: Non-Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Pancreas Cancer
Drug: pemetrexed
pemetrexed 500 mg/m2 IV day 1 of each 21 day cycle until disease progression or unacceptable toxicity for a maximum of 8 cycles
Other Names:
  • Alimta
  • LY231514
  • NSC# 698037
Experimental: chemotherapy
Intervention: Drug: pemetrexed
Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
July 2009
July 2009   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Histologically confirmed adenocarcinoma of the pancreas
  • Prior treatment for distant or locally advanced disease with gemcitabine-based therapy
  • Measurable or evaluable disease
  • ECOG performance status 0-2
  • Adequate hematological parameters
  • Adequate baseline liver function
  • At least 28 days from any major surgery
  • At least 2 weeks from the last radiation treatment
  • Must have recovered from reversible toxicities of prior chemotherapy
  • Must be able to discontinue any nonsteroidal anti-inflammatory medications
  • Must be willing to receive intramuscular vitamin B12 shots and take oral folate supplements

Exclusion Criteria:

  • Any prior treatment with pemetrexed
  • More than one prior chemotherapy regimen
  • HIV positive on antiretroviral therapy
  • Pregnant or lactating
  • Prior organ allograft
  • On concurrent antitumor therapy including radiation therapy or other chemotherapies
  • Creatinine clearance 45 ml/min or less
  • Absolute neutrophil count < 1500
  • Platelets < 75,000
  • Bilirubin > 1.5 times the upper limit of normal
  • Transaminases > 3 times the upper limit of normal except in known liver metastasis wherein they may be </= 5 times upper limit of normal
  • Clinically significant ascites or pleural effusion that cannot be drained
  • Any medical or psychiatric condition that may interfere with the ability to comply with protocol treatment
18 Years and older
Contact information is only displayed when the study is recruiting subjects
United States
IIT2007022, 2007-022
Jimmy Hwang, MD, Georgetown University
Georgetown University
Eli Lilly and Company
Principal Investigator: Jimmy J Hwang, M.D. Georgetown University
Georgetown University
March 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP